key: cord-0817669-d8q40w1t
authors: Rhee, Chanu; Kanjilal, Sanjat; Baker, Meghan; Klompas, Michael
title: Duration of SARS-CoV-2 Infectivity: When is it Safe to Discontinue Isolation?
date: 2020-08-25
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa1249
sha: d586fc05876fc109ca7c86757c4d170c1dc76504
doc_id: 817669
cord_uid: d8q40w1t

Defining the duration of infectivity of SARS-CoV-2 has major implications for public health and infection control practice in healthcare facilities. Early in the pandemic, most hospitals required two negative RT-PCR tests before discontinuing isolation in patients with Covid-19. Many patients, however, have persistently positive RT-PCR tests for weeks to months following clinical recovery and multiple studies now indicate that persistently positive RT-PCRs generally do not reflect replication-competent virus. SARS-CoV-2 appears to be most contagious around the time of symptom onset and infectivity rapidly decreases thereafter to near-zero after about 10 days in mild-moderately ill patients and 15 days in severely-critically ill and immunocompromised patients. The longest interval associated with replication-competent virus thus far is 20 days from symptom onset. This review summarizes evidence-to-date on the duration of infectivity of SARS-CoV-2 and how this has informed evolving public health recommendations on when it is safe to discontinue isolation precautions.

A c c e p t e d M a n u s c r i p t 4 symptomatic people to transmit virus prior to symptom onset is well documented. [9] [10] [11] [12] [13] SARS-CoV-2 therefore appears to have similar transmission dynamics to influenza, which is also contagious before through several days after symptom onset. [14] [15] [16] 

Early in the pandemic, WHO and CDC recommended test-based clearance with at least two negative RT-PCR tests for patients with Covid-19. This strategy, however, can lead to prolonged isolation as some patients have positive RT-PCR assays for weeks if not months. [17] [18] [19] [20] [21] [22] [23] . Sicker patients tend to have detectable RNA for longer periods, but prolonged PCR positivity also occurs in mildly ill and asymptomatic individuals. [6, 8, [24] [25] [26] [27] [28] [29] The duration of PCR positivity appears to be longer in lower respiratory tract versus upper respiratory tract samples as well as in stool samples. [27, [30] [31] [32] [33] In addition, some patients recover from Covid-19, have two negative tests, and then test positive again even in the absence of new symptoms. [34, 35] 

While PCR tests are reported as a binary result, the cycle threshold (Ct) value -the number of PCR cycles required for the sample fluorescence to exceed a predefined threshold --provides additional useful information. The Ct value is inversely related to the amount of nucleic acid present in the sample, such that every increase in Ct value of ~3.3 corresponds to a 10-fold reduction in the amount of nucleic acid. [36] Most SARS-CoV-2 PCR assays use a Ct cutoff of <40 for positivity. Patients in the early stages of infection usually have Ct values of 20-30 or less. [37] Ct values tend to increase A c c e p t e d M a n u s c r i p t 5 thereafter, reflecting progressively lower amounts of viral RNA as the immune response clears the infection.

Ct values must be interpreted with caution as they do not reflect a true viral load, which requires standardization using reference curves. As such, they are not directly comparable across assays.

[38] Furthermore, differences in specimen collection quality and reaction conditions can introduce further variation. [39, 40] This imprecision in PCR testing is most apparent when the amount of viral nucleic acid at the sampling site approaches the limit of detection for the assay and is the most common reason for why some patients alternate between testing negative and testing positive. Lastly, only traditional real-time PCR assays produce a Ct value; assays that use isothermal amplification do not product a Ct value and nested PCR assays are not designed for quantitative interpretation. [41] 

It is now clear that persistent RNA detection does not necessarily translate into viable virus that can infect others. Subgenomic RNA fragments associate tightly with intracellular vesicles that protect them from degradation by host enzymes, which may explain why PCR tests are persistently positive in many patients. [42] The ability of SARS-CoV-2 to replicate in cultured cells is a better surrogate for infectivity. In a hamster study, for example, transmissibility of SARS-CoV-2 correlated with detection of infectious virus by culture, but not by RT-PCR positivity alone. [43] The possibility of human transmission despite non-culturable virus cannot be ruled out as no study has attempted to link the presence of culturable virus directly to infectivity in humans.

However, an increasing body of evidence suggests that time from symptom onset and Ct A c c e p t e d M a n u s c r i p t 6 values are both useful proxies for infectivity. Notably, SARS-CoV-2 viral culture is not used in routine practice as it can only performed by specialized laboratories that can meet minimum standards for biosafety. Table 1 summarizes the evidence that persistently positive SARS-CoV-2 RNA PCRs are due to residual viral "debris" rather than replication-competent virus. The first study to make this suggestion was an analysis of 9 hospitalized patients with mildmoderate disease. [6] RNA was detectable by PCR for weeks after onset of symptoms in some patients; however, virus was only isolated by culture during the first week of symptoms and could not be cultured from any samples taken >8 days following symptom onset.

Likewise, the US CDC reported they have not been able to isolate culture replication-competent virus from patients >9 days from symptom onset. [44] These data were generated from adult patients spanning a range of ages and severities of illness, although CDC did not specify the number of patients in their analysis. Attempts to culture virus from upper respiratory specimens were unsuccessful when PCR Ct values were higher than 35 (i.e., a low but detectable range of viral nucleic acid). Ct values from upper respiratory specimens were high following recovery from clinical illness, suggesting viral debris rather than replication-competent virus. Lastly, they reported that they have not cultured infectious virus from urine or from feces, suggesting these sources pose minimal risk of transmission particularly following hand hygiene. Note, however, that investigators have been able to culture infectious virus from feces in at least one patient. [45] Similar results were reported in two studies from Southern France that retrospectively examined the effect of hydroxychloroquine and azithromycin on clinical and virologic outcomes. [46, 47] In the first analysis, 183 PCR-positive samples Although the duration of infectivity is generally longer in severe illness, outliers may be possible. One case report from Taiwan, for example, noted infectious shedding by viral cell culture in the sputum 18 days after symptom onset in a patient with a mild febrile illness. [51] In addition, effective antiviral therapy is associated with a shorter time to negative SARS-CoV-2 viral load, although its impact on transmissibility has not yet been established. [52] Epidemiological Data on Transmissibility

The data on duration of viral recovery in cell culture following symptom onset are mirrored by data on transmission rates. In a prospective study conducted in Taiwan, 100 confirmed Covid-19 cases and their contacts were identified and the secondary clinical attack rate was measured for different time intervals from symptomonset. [53] There were 2,761 close contacts of the 100 cases; the secondary attack rate was 0.7% amongst the 1,818 people with contact with case patients within 5 days of symptom onset and 0% amongst the 852 people with contact >5 days after symptom onset. As with other studies, attack rates were highest among household and family contacts (~5%) and substantially lower amongst healthcare contacts (0.9%). Notably, A c c e p t e d M a n u s c r i p t 9 though, only 6 of the confirmed index cases had severe disease; the 786 close contacts of these severely ill patients were about four times more likely to acquire infection compared to the 1,097 close contacts of 56 patients with mild disease.

Investigators from Guangdong Province, China, analyzed 619 hospitalized patients with Covid-19 who were discharged after resolution of fever, improvement in respiratory symptoms, and 2 consecutive negative PCR samples >24 hours apart on both respiratory tract and gastrointestinal tract samples. [54] All discharged cases were 

An important question is whether individuals who have recovered from Covid-19 are vulnerable to SARS-CoV-2 re-infection and how long immunity might last.

Animal studies demonstrate that infection provides at least short-term immunity. One group of investigators experimentally infected 9 rhesus macaques with SARS-CoV-2, after which all developed neutralizing antibodies. [56] When the monkeys were re- In humans, we are unaware of any convincing report to date of a recovered patient who subsequently became symptomatic from a new SARS-CoV-2 infection. As 

In summary, based on a rapidly expanding evidence base, we currently draw the following conclusions regarding the timing and duration of SARS-CoV-2 transmissibility A c c e p t e d M a n u s c r i p t 12 5 . Infection confers at least short-term immunity; however, the durability of immunity is unclear. Serial serologies raise the possibility of waning antibodies 2-3 months after infection but the clinical significance of this finding is unknown.

These data have informed evolving national and international public health recommendations ( Table 2 ). WHO, for example, initially recommended two negative PCR results on sequential samples taken >24 hours apart in clinically recovered patients before discontinuing isolation. On May 27, WHO shifted to recommending isolation for 10 days after symptom onset plus at least 3 additional days without symptoms. [64] In asymptomatic patients, WHO recommends discontinuing isolation 10 days after the positive PCR test. WHO still allows providers the option of using serial negative tests to clear patients but acknowledges that some patients have prolonged viral RNA detection by PCR that does not correlate with infectivity.

In July and August, CDC modified their guidance to a more nuanced approach based on severity-of-illness and immunocompetence.

[65] Specifically, while CDC still recommends 10 days of isolation from symptom onset (including >24 hours since resolution of fever and improvement in symptoms) for mild-moderately ill patients without severely immunocompromising conditions, they now recommend at least 10 days and up to 20 days for patients with severe-critical illness or severely immunocompromising conditions. For asymptomatic patients, 10 days is recommended from the first positive PCR test (and up to 20 days for severely immunocompromised patients). Moreover, CDC recommends avoiding test-based clearance given the evidence that people with persistently positive PCR tests are not contagious. Test-based clearance should be reserved for rare cases when there is a A c c e p t e d M a n u s c r i p t 13 need to discontinue isolation early, or potentially to inform a decision to prolong isolation for severely immunocompromised patients.

CDC now recommends that patients who have recovered from Covid-19 and remain asymptomatic should not be retested within 3 months after symptom onset, even if they had close contact with another infected person. [44] This is based on observations that persons infected with related endemic human betacoronaviruses only become susceptible to reinfection after about 90 days, and therefore a positive SARS-CoV-2 PCR test within 90 days of an initial infection most likely represents persistent viral debris rather than reinfection. For new symptoms potentially consistent with COVID-19 that develop within 3 months and are not clearly attributable to another diagnosis (such as influenza), CDC states that isolation may be warranted while evaluating for possible SARS-CoV-2 reinfection, in consultation with an infectious disease or infection control expert.

The optimal approach for isolating asymptomatic patients who test positive again >90 days from the original infection (for example, as part of a contact tracing investigation, or during routine screening upon admission to a healthcare facility) remains uncertain. This phenomenon, in our experience, is not uncommon, and most of these patients have high PCR Ct values suggestive of residual viral debris. We believe that the decision to isolate should be made on a case-by-case basis in consultation with infectious disease / infection control experts and /or local public health authorities, taking into account the patient's medical history, time from initial positive test, PCR Ct value, and immune status. Given the uncertainty regarding duration of immunity, we A c c e p t e d M a n u s c r i p t 14 believe it is prudent at this time to test all recovered patients who develop new symptoms > 3 months after initial infection and to isolate them if the PCR test is positive.

Much progress has been made in understanding the transmission dynamics of SARS-CoV-2 and duration of infectivity. WHO and CDC have modified their recommendations in response to data indicating that infectivity decreases to essentially zero after about 10 days from symptom onset in mild-moderately ill patients and after about 15 days in critically ill and immunocompromised patients, with a maximum reported interval thus far of 20 days. Additional data confirming these findings in larger and more diverse cohorts are needed to provide further reassurance as to the safety of discontinuing isolation for critically ill, deeply immunocompromised, and otherwise high-risk patients, and to define the optimal approach to retesting and isolation in patients who have recovered from Covid-19. collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

(6U54CK000484-04-02) and the Agency for Healthcare Research and Quality (K08HS025008 to C.R.).

MK and CR report personal fees from UpToDate, outside the submitted work. All other authors have no potential conflicts to disclose.

Clinical Characteristics of Coronavirus Disease 2019 in China

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Virological assessment of hospitalized patients with COVID-2019

Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States

Temporal dynamics in viral shedding and transmissibility of COVID-19

Asymptomatic cases in a family cluster with SARS-CoV-2 infection

Presumed Asymptomatic Carrier Transmission of COVID-19

Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility -King County

Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany

A COVID-19 Transmission within a family cluster by presymptomatic infectors in China

Time lines of infection and disease in human influenza: a review of volunteer challenge studies

The Dynamic Relationship Between Clinical Symptomatology and Viral Shedding in Naturally Acquired Seasonal and Pandemic Influenza Virus Infections

Viral shedding and clinical illness in naturally acquired influenza virus infections

Prolonged persistence of SARS-CoV-2 in the upper respiratory tract of asymptomatic infected individuals

Persistent severe acute respiratory syndrome coronavirus 2 detection after resolution of coronavirus disease 2019-associated symptoms/signs

Positive results for patients with COVID-19 discharged form hospital in Chongqing, China

Duration of viral shedding in asymptomatic or mild cases of novel coronavirus disease 2019 (COVID-19) from a cruise ship: A single-hospital experience in

Quantifying the prevalence of SARS-CoV-2 long-term shedding among non-hospitalized COVID-19 patients

Duration of viral shedding in asymptomatic or mild cases of novel coronavirus disease 2019 (COVID-19) from a cruise ship: A single-hospital experience in

Dynamic profile of RT-PCR findings from 301 COVID-19 patients in Wuhan, China: A descriptive study

Clinical characteristics and factors associated with long-term viral excretion in patients with SARS-CoV-2 infection: a single center 28-day study

Case Report: Viral Shedding for 60 Days in a Woman with COVID-19

Positive SARS-CoV-2 RNA recurs repeatedly in a case recovered from COVID-19: dynamic results from 108 days of follow-up

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China

Factors associated with prolonged viral RNA shedding in patients with COVID-19

Factors associated with duration of viral shedding in adults with COVID-19 outside of Wuhan, China: A retrospective cohort study

Differences of SARS-CoV-2 Shedding Duration in Sputum and Nasopharyngeal Swab Specimens among Adult Inpatients with COVID-19

Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau

Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients

Duration of Respiratory and Gastrointestinal Viral Shedding in Children With SARS-CoV-2: A Systematic Review and Synthesis of Data. The Pediatric infectious disease journal

PCR Assays Turned Positive in 25 Discharged COVID-19 Patients

Positive RT-PCR tests among discharged COVID-19 patients in Shenzhen, China. Infection control and hospital epidemiology : the official journal of the Society of

To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold Value

Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA 2020. 38. van Kasteren PB, van der Veer B, van den Brink S, et al. Comparison of seven commercial RT-PCR diagnostic kits for COVID-19

Interpreting the COVID-19 Test Results: A Guide for Physiatrists

Evaluation of Transport Media and Specimen Transport Conditions for the Detection of SARS-CoV-2 Using Real Time Reverse Transcription PCR

College of American Pathologists (CAP) Microbiology Committee Perspective: Caution must be used in interpreting the Cycle Threshold (Ct) value

SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

Centers for Disease Control and Prevention: Symptom-Based Strategy to Discontinue Isolation for Persons with COVID-19

Infectious SARS-CoV-2 in Feces of Patient with Severe COVID-19

Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. European journal of clinical microbiology & infectious diseases : official publication of the

Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France

Predicting infectious SARS-CoV-2 from diagnostic samples

Immunological and viral correlates of COVID-19 disease severity: a prospective cohort study of the first 100 patients in Singapore

Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants

Prolonged virus shedding even after seroconversion in a patient with COVID-19

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset

Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR

Korean CDC: Findings from investigation and analysis of re-positive cases

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques

A serological assay to detect SARS-CoV-2 seroconversion in humans

Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications

Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Rapid Decay of Anti-SARs-CoV-2 Antibodies in Persons with Mild Covid-19

Centers for Disease Control and Prevention: Discontinuation of Transmission-Based Precautions and Disposition of Patients with COVID-19 in Healthcare Settings

A c c e p t e d M a n u s c r i p t 16 A c c e p t e d M a n u s c r i p t 17 A c c e p t e d M a n u s c r i p t 18 A c c e p t e d M a n u s c r i p t 19 A c c e p t e d M a n u s c r i p t 20 

A c c e p t e d M a n u s c r i p t Figure 1